Evotec AG has entered into a non-exclusive license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology. Evotec gains access to IP related to CRISPR-Cas9 and will apply the technology to its drug discovery offerings and R&D activities, as well as for the development of research tools in target identification, and to further strengthen its post phenotypical screening target deconvolution platform. Dr. Mario Polywka, chief operating o...